Genentech

Source: Wikipedia, the free encyclopedia.

Genentech, Inc.
Roche
Websitegene.com

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.[5] Historically, the company is regarded as the world's first biotechnology company.[6]

As of July 2021, Genentech employed 13,539 people.[7]

History

The company was founded in 1976 by venture capitalist

plasmid vector.[10] While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company.[8][11] Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977.[12] David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin
in 1978.

In 1990

F. Hoffmann-La Roche AG acquired a majority stake in Genentech.[13]

In 2006 Genentech acquired

Xolair and development was completed in collaboration with Novartis and Genentech; the acquisition allowed Genentech to keep more of the revenue.[14]

In March 2009 Roche acquired Genentech by buying shares it didn't already control for approximately $46.8 billion.[15][16][17]

In July 2014, Genentech/Roche acquired Seragon for its pipeline of small-molecule cancer drug candidates for $725 million cash upfront, with an additional $1 billion of payments dependent on successful development of products in Seragon's pipeline.[18]

Research

Genentech is a pioneering research-driven biotechnology company[13] that has continued to conduct R&D internally as well as through collaborations.[19][20]

Genentech's research collaborations include:

  • In 2008 Genentech entered into a collaboration with Roche and its subsidiary GlycArt to develop obinutuzumab.[21]
  • In February 2010 Genentech entered into a collaboration with University of California, San Francisco after having worked with them in about fifteen other collaborations, this time to collaborate on small molecule drug discovery in neurology.[22]
  • In October 2014 Genentech paid $150M upfront to collaborate with Iowa-based NewLink Genetics on checkpoint inhibitors.[23]
  • In June 2015 it entered into a wide-ranging partnership with The Data Incubator to help train and hire the next generation of data scientists at the company.[24]
  • In January 2015 it signed a $60M deal with 23andMe that gave Genentech access to the genomic and patient-reported data held by 23andMe.[25]
  • In October 2015 it started a collaboration with Nimbus Therapeutics to develop leads from Nimbus' in silico drug discovery platform.[26]
  • In June 2016 Genentech partnered Epizyme to conduct clinical trials exploring whether Epizyme's EZH2 inhibitor tazemetostat would be synergistic with Genentech's atezolizumab.[27]
  • In August 2016, the company began a collaboration with Carmot Therapeutics in which Carmot will discover new candidates and Genentech will develop them.[28]
  • In September 2016 Genentech partnered with the Israeli company BioLineRx on a checkpoint inhibitor that Genentech intended to pair with its own atezolizumab.[29]

Facilities

Building 31, one of the newer buildings at Genentech headquarters

Genentech's corporate headquarters are in South San Francisco, California (37°39′25″N 122°22′44″W / 37.657°N 122.379°W / 37.657; -122.379 (Genentech)), with additional manufacturing facilities in Vacaville, California; Oceanside, California; and Hillsboro, Oregon. In March 2024, it was announced the Swiss pharmaceutical company, Lonza had acquired the Vacaville site from parent-company, Roche for $1.2 billion.[30]

In December 2006, Genentech sold its

Lucentis (ranibizumab injection) bulk drug substance.[citation needed
]

In 2023, the company announced plans to close down its manufacturing facility in South San Francisco, while expanding its manufacturing capabilities in Oceanside.[31][32]

Public-private engagement

Political lobbying

Genentech is a donor to the Center for Health Care Strategies, a non-governmental organization that lobbies the

United States Government on issues related to Medicaid.[33]

Genentech Inc Political Action Committee

Genentech Inc Political Action Committee is a U.S. Federal

Political Action Committee (PAC), created to "aggregate contributions from members or employees and their families to donate to candidates for federal office".[34]

Controversy

Disputes

In November 1999, Genentech agreed to pay the

somatotropin/human growth hormone), independently of UCSF. A jury ruled that the university's patent was valid in July 1999, but wasn't able to decide whether Protropin was based upon UCSF research or not. Protropin, a drug used to treat dwarfism, was Genentech's first marketed drug and its $2 billion in sales has contributed greatly to its position as an industry leader.[citation needed] The settlement was to be divided as follows: $30 million to the University of California General Fund, $85 million to the three inventors and two collaborating scientists, $50 million towards a new teaching and research campus for UCSF, and $35 million to support university-wide research.[35]

In 2009,

Congress during the national health care reform debate.[36] Two U.S. Representatives, Joe Wilson and Blaine Luetkemeyer
, both issued the same written statements: "One of the reasons I have long supported the U.S. biotechnology industry is that it is a homegrown success story that has been an engine of job creation in this country. Unfortunately, many of the largest companies that would seek to enter the biosimilar market have made their money by outsourcing their research to foreign countries like India." The statement was originally drafted by lobbyists for Genentech.

Products timeline

Diversity and inclusion efforts

Led by Chief Diversity Officer, Quita Beeler Highsmith, Genentech also co-hosts the Health Equity Symposium, a collaboration with healthcare institutions and community organizations to address inequities among diverse populations.[37]

In 2022, Genentech won the following awards for their diversity and inclusion efforts:

  • Forbes named Genentech one of “America's Best Employers for Diversity”[38]
  • Forbes named Genentech one of “America’s Best Large Employers”[39]
  • Human Rights Campaign Diversity scoring Genentech 100 on the “Corporate Equality Index”[40]

Awards and recognitions

See also

References

  1. ^ "DEPARTURE OF ALEXANDER HARDY & APPOINTMENT OF ASHLEY MAGARGEE AS INTERIM CHIEF EXECUTIVE OFFICER GENENTECH". Genentech. Retrieved November 3, 2023.
  2. ^ Taylor, Nick Paul (May 11, 2020). "Genentech lures Regev from Broad Institute to lead research and early development". FierceBiotech. Retrieved May 25, 2020.
  3. ^ "Changes to the Roche Enlarged Corporate Executive Committee" (Press release). Basel, Switzerland: F. Hoffmann-La Roche Ltd. globenewswire. May 11, 2020. Retrieved May 25, 2020.
  4. ^ "Genentech".
  5. ^ "About Us". Gene.com. Archived from the original on August 4, 2014. Retrieved August 22, 2014.
  6. S2CID 4357773
    .
  7. ^ "Working at Genentech". Great Place to Work. Retrieved November 18, 2021.
  8. ^
    S2CID 4357773
    .
  9. ^ Genentech. "Corporate Overview". Archived from the original on April 18, 2012. Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including Cetus Corporation which was founded in 1971.
  10. PMID 4594039
    .
  11. PBS. Archived
    from the original on June 20, 2012. Retrieved August 28, 2017.
  12. PMID 412251
    .
  13. ^ a b Fisher, Lawrence M. (October 1, 2000). "Genentech: Survivor Strutting Its Stuff". The New York Times. Archived from the original on April 4, 2017. Retrieved February 19, 2017.
  14. ^ "Genentech strikes $919M deal to buy Tanox". FierceBiotech. November 9, 2006. Archived from the original on April 4, 2017.
  15. ^ Morse, Andrew (May 10, 2006). "Chugai Shares Post Healthy Gain On Prospects for Cancer Drug". The Wall Street Journal. Retrieved September 26, 2008.
  16. ISSN 1935-472X. Archived
    from the original on February 3, 2009. Retrieved September 26, 2008.
  17. ISSN 0362-4331
    . Retrieved April 3, 2020.
  18. Genetic Engineering & Biotechnology News. Archived
    from the original on July 14, 2014. Retrieved July 2, 2014.
  19. ^ "Three Years After Merger, Genentech R&D Outshines That of Roche's | GEN News Highlights". Genetic Engineering News. July 3, 2012. Archived from the original on April 5, 2017. Retrieved September 18, 2016.
  20. ^ "Living 10 Years in the Future". Genentech. Archived from the original on August 1, 2016.
  21. ^ Carroll, John (October 3, 2008). "Genentech teams with Glycart on antibody program". FierceBiotech. Archived from the original on April 4, 2017. Retrieved September 18, 2016.
  22. ^ "UCSF enters drug discovery agreement with Genentech". FierceBiotech. February 19, 2010. Archived from the original on April 4, 2017. Retrieved September 18, 2016.
  23. ^ Carroll, John (October 20, 2014). "Genentech pays $150M upfront to partner on NewLink's immuno-oncology drug". FierceBiotech. Archived from the original on June 14, 2016. Retrieved September 18, 2016.
  24. ^ "The Promise and Challenge of Big Data for Pharma". Archived from the original on April 5, 2017. Retrieved April 5, 2017.
  25. ^ Herper, Matthew. "Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan". Forbes. Archived from the original on August 16, 2017. Retrieved August 16, 2017.
  26. ^ Garde, Damian (October 20, 2015). "Genentech co-signs Nimbus' computer-aided R&D with an oncology pact". FierceBiotech. Archived from the original on July 11, 2016. Retrieved September 18, 2016.
  27. ^ Lawrence, Stacy (June 23, 2016). "Epizyme nabs combo trial deal with Genentech for NHL candidate | FierceBiotech". www.fiercebiotech.com. Archived from the original on September 6, 2016. Retrieved September 18, 2016.
  28. Genetic Engineering & Biotechnology News
    (Paper). 36 (14): 17. August 2016.
  29. ^ Lawrence, Stacy (September 7, 2016). "Genentech, BioLineRx pair up a checkpoint inhibitor combo". FierceBiotech. Archived from the original on September 11, 2016. Retrieved September 18, 2016.
  30. ^ "Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn - Pharmafile". pharmafile.com. March 20, 2024. Retrieved March 20, 2024.
  31. ^ Varian, Ethan (March 25, 2023). "Genentech lays off 265 workers in South San Francisco, closes manufacturing plant". The Mercury News.
  32. ^ Rocha, Natalie (February 21, 2023). "Genentech expands in Oceanside with $450M biotech manufacturing facility and 150 jobs". The San Diego Union-Tribune.
  33. ^ "History & Funders". Center for Health Care Strategies. 2021. Archived from the original on July 12, 2022. Retrieved July 12, 2022.
  34. ^ Genentech Inc Political Action Committee, Bloomberg Business, n.d., archived from the original on August 20, 2015, retrieved July 17, 2015
  35. ^ Genentech Press Release. "University of California and Genentech Settle Patent Infringement Lawsuits". Genentech, Inc. Archived from the original on August 22, 2013. Retrieved November 16, 2015.
  36. ^ Pear, Robert. "In House, Many Spoke with One Voice: Lobbyists" Archived August 31, 2019, at the Wayback Machine, New York Times, November 15, 2009.
  37. ^ "College of Medicine receives the Genentech Health Equity & Diversity in STEM Innovation Fund | Elson S. Floyd College of Medicine | Washington State University". Retrieved February 24, 2023.
  38. ^ COUNCIL", "JARED. "America's Best Employers For Diversity 2022". Forbes. Retrieved February 24, 2023.
  39. ^ SCHWARZ", "ALAN. "America's Best Large Employers 2023". Forbes. Retrieved February 24, 2023.
  40. ^ "Human Rights Campaign". Human Rights Campaign. Retrieved February 24, 2023.
  41. ^ "Genentech". Fortune. Retrieved March 24, 2020.
  42. ^ "Working Mother Magazine". Archived from the original on April 4, 2011. Retrieved February 20, 2020.
  43. ^ "TechNet". Archived from the original on February 3, 2009. Retrieved May 17, 2008.
  44. ^ "Nature". Archived from the original on February 3, 2009. Retrieved May 17, 2008.
  45. ^ "Science Magazine". October 8, 2010. Archived from the original on February 10, 2011. Retrieved February 15, 2011.
  46. ^ "No. 58: Genentech, Inc". ComputerWorld Magazine. Archived from the original on January 16, 2009.
  47. ^ "Glassdoor.com Lists Naughtiest and Nicest C.E.O.'s of 2008". The New York Times. December 26, 2008. Archived from the original on October 4, 2011. Retrieved May 3, 2010.
  48. ^ "Innovation Awards: And the winners are..." The Economist. November 30, 2013. Archived from the original on November 7, 2017. Retrieved August 28, 2017.

Further reading

External links

Wikimedia Commons has media related to Genentech.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Genentech&oldid=1220772271"